Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment

Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment

November 04, 2008

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study of Liver Disease's (AASLD) Liver Meeting 2008 in San Francisco.

The current standard of care treatment for HCV infection, pegylated interferon (Peg-IFN) combined with ribavirin (RBV), is effective in 30 to 50 percent of patients infected with chronic genotype 1 HCV infection, the most common type in the United States. The development of new therapies and strategies for treating HCV, particularly the introduction of direct antivirals, may offer patients a new option with shorter treatment duration.




TMC435 Phase IIa Study Results

In interim findings from the first 28 days of treatment for the first cohort of fifty (50) treatment naďve HCV+, genotype 1, patients (once daily dose of 25 mg or 75 mg TMC435 versus placebo), both doses showed dose-dependent antiviral activity. TMC435 was administered in combination with PegIFNα-2a/RBV (triple therapy) for 28 days or as monotherapy for seven days and, thereafter, in combination with PegIFNα-2a/RBV (triple therapy) for three weeks. There were neither serious adverse events, nor grade 3 or 4 adverse events, related to TMC435 or any safety-related treatment discontinuations during this 28 day treatment period.

The most common adverse events associated with TMC435 were nausea, diarrhea, and headache. There were no clinically relevant changes in laboratory parameters, ECGs, or vital signs. Steady-state plasma trough levels of TMC435 25 mg and 75 mg represented ~10 and >30-fold excess above the HCV replicon EC50 value, respectively.

Mean reductions of HCV RNA from baseline to day seven with TMC435 alone and in triple therapy were 2.63 and 3.47 log10 IU/mL, respectively, in the 25 mg arm, and 3.43 and 4.55 log10 IU/mL in the 75 mg arm. In the 75 mg four-week triple therapy arm, no viral breakthrough was observed; 9/9 patients achieved HCV RNA below lower limit of quantification (<25 IU/mL) and 8/9 patients achieved undetectable HCV RNA (<10 IU/mL) at day 28 (RVR=89 percent).

"These data provide important information about an emerging new approach to treating HCV," said Professor and Chairman Michael Manns, Hannover Medical School, Germany. "The discovery and development of new treatments is critical to improving the standard of care for the millions of people living with this disease."

As a global virology leader committed to patient care, Tibotec uses innovative science and expertise to research, develop, and manufacture, drugs for medical conditions with an unmet need. The company has successfully launched two antiviral medications for the treatment of HIV and is now building a portfolio of novel antiviral therapies for HCV with the goal of becoming a prominent leader in the treatment of this infectious disease.

TMC435 was discovered through a drug discovery collaboration between Medivir and Tibotec. Tibotec has the right to develop and commercialize the compound throughout the world, excluding the Nordic countries. In addition to TMC435, Tibotec has another PI in phase III development for the treatment of chronic HCV infection.

"Tibotec is committed to evaluating the safety and efficacy of TMC435 in clinical studies to determine its potential use in people with HCV," said Roger Pomerantz, M.D., president of Tibotec Research and Development. "This is an important step in our mission of addressing treatment challenges of infectious diseases, including HCV, HIV and tuberculosis."

Zeno Group



Related Hepatitis Current Events and Hepatitis News Articles Hepatitis Current Events and Hepatitis News RSS Hepatitis Current Events and Hepatitis News RSS
Toward explaining why hepatitis B hits men harder than women
Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women.

Largest-ever database for liver proteins may lead to treatments for hepatitis
Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ.

Mount Sinai finds those with more difficult to treat forms of HCV are half as likely to get treated
A new study by Mount Sinai researchers has for the first time found that patients with more difficult to treat forms of hepatitis C are half as likely to initiate treatment for the disease, when compared to patients with hepatitis C that is easier to treat.

Extending treatment after liver transplant may benefit patients with hepatitis C recurrence
Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.

Hepatitis B does not increase risk for pancreatic cancer
A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor.

Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.

Liver cells grown from patients' skin cells
Scientists at The Medical College of Wisconsin in Milwaukee have successfully produced liver cells from patients' skin cells opening the possibility of treating a wide range of diseases that affect liver function.

Injury and hazards in home health care nursing are a growing concern
Patients continue to enter home healthcare ''sicker and quicker," often with complex health problems that may require extensive nursing care.

Medication effective for acute liver failure in early stages of disease
The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found.

New aging studies improving vaccine efficacy for the elderly
A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects.
More Hepatitis Current Events and Hepatitis News Articles
Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease

Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease
by Melissa Palmer (Author)

In the United States alone, more than four million people are infected with the hepatitis C virus, and chronic liver disease is the twelfth leading cause of death.

In this revised and updated edition of her groundbreaking 2000 book, renowned hepatologist Dr. Melissa Palmer discusses all facets of liver disease, from symptoms and tests to treatment options and lifestyle changes. In addition, this comprehensive handbook reveals cutting-edge research on the dangers of hepatitis C, one of the world's fasting-growing microbial threats.

Living With Hepatitis C For Dummies

Living With Hepatitis C For Dummies
by Nina L. Paul (Author), Gina Pollichino (Foreword)

A comprehensive, empathetic guide for anyone suffering from this serious liver disease

Approximately 4 million Americans and 170 million people worldwide suffer from hepatitis C, a viral liver disease that is treatable but not curable. It accounts for more than 40 percent of U.S. liver disease deaths–about 8,000 to 10,000 people annually–and is the most common reason for liver transplantation. This compassionate guide explains how hepatitis C affects the liver and the body and provides solid advice on today’s treatment options–from drugs (and their side effects) to transplants and alternative therapies–as well as tips on dealing with the emotional and financial burdens the disease brings with it.

Nina L Paul, PhD (New York, NY) earned her doctorate in infectious...

HEPATITIS GIANT MICROBE

HEPATITIS GIANT MICROBE
by Giant Microbes

HAV is spread primarily by unsanitary food and water ? HBV is transmitted in bodily fluids and can cause chronic liver disease ? HCV is perhaps the most dangerous: no vaccine is available

? HDV occurs only in the presence of HBV ? HEV is relatively mild
and non-chronic ? HFV and HGV are newly identified; their connection with liver disease is debated

Understanding Hepatitis B (Home Use)

Understanding Hepatitis B (Home Use)

Part of the award winning public television series Healthy Body/Healthy Mind. Hepatitis B is the most common Hepatitis virus affecting more than a billion people world wide. Unfortunately many of the people who carry the virus don't even know they're infected. As a result the infection continues to proliferate. But there is a serious effort to eradicate this virus, through treatment and vaccine programs. The important first step is for those in the "at risk" categories to be tested. In this program we hear first hand accounts of what could happen if the infection remains untreated for many years.

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.



Home Access Hepatitis C Check 1 ea

Home Access Hepatitis C Check 1 ea
by Home Access

At-Home Telemedicine Test Service for Hepatitis C*.
Confidentia

  Aids & Hepatitis Digest
by Ccm International Ltd


Provides information to Air Force comptroller personell relating to mission accomplishment, to assist them in solving problems and improving efficiency of operation and to communicate new developments and techniques


The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing

The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing
by Misha Ruth Cohen O.M.D. L. Ac. (Author), Robert Gish (Author), Kalia Doner (Author)

A fully updated and revised edition of an important health guide, including the latest information on optimum interferon protocol. Hepatitis C has been called "the emergent and preeminent public-health problem of the twenty-first century--surpassing HIV." It has also been dubbed "The Shadow Epidemic," because it is one of the most clandestine of viruses and infects healthy people who have no idea they are being attacked by something they can't even detect. Now, the two experts on Hepatitis C who teamed up to write the first comprehensive guide to orthodox and alternative treatment options have revised and fully updated the book to include recent findings in the field. Along with programs for self-care, nutritional and fitness plans and a comprehensive Western and Chinese medical...

Native Remedies Liver Doctor and Detox Drops ComboPack

Native Remedies Liver Doctor and Detox Drops ComboPack
by Native Remedies

The ComboPack of Liver Dr. and Detox Drops consists of multiple remedies that work well together to provide increased support for your condition. This ComboPack helps to improve liver functioning and aids in detoxifying the system. The Liver Dr. helps to improve liver health and functioning while the Detox Drops assist in the elimination of toxins from the body.

Understanding Hepatitis Anatomical Chart Laminated (In Stock)-9992PL1.5

Understanding Hepatitis Anatomical Chart Laminated (In Stock)-9992PL1.5
by Anatomical Chart Company

Defines viral hepatitis and the types of hepatic viruses that cause this disease: Hepatitis A, B, C, D, E, and recently discovered viruses G and TTV (Transfusion Transmitted Virus). Talks about modes of tranmission and illustrated the complications of hepatitis. Illustrates the anatomy of the liver, pancreas and surrounding structures, including veins and arteries. Shows 3 liver biopsies: normal, mild hepatitis and moderate. Lists the signs and symptoms which progress by stages.

Hepatitis C Awareness Ribbon Mouse Pad

Hepatitis C Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Hepatitis C Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Hepatitis C Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Hepatitis C Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

© 2009 BrightSurf.com